Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aziyo Biologics ( (ELUT) ) has shared an announcement.
On October 10, 2025, Elutia Inc. announced the election of Guido J. Neels to its Board of Directors, effective October 9, 2025, and his appointment to the Audit Committee. This move follows the resignations of board members Maybelle Jordan and W. Matthew Zuga, effective October 8, 2025. Neels, with over 40 years of experience in the medical technology sector, is expected to provide valuable insights as Elutia focuses on leveraging its drug-eluting biomatrix technology to build shareholder value, particularly after its recent EluPro divestiture.
The most recent analyst rating on (ELUT) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.
Spark’s Take on ELUT Stock
According to Spark, TipRanks’ AI Analyst, ELUT is a Neutral.
Aziyo Biologics’ overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While the earnings call highlighted some positive developments, the company’s financial instability and valuation concerns weigh heavily on the score.
To see Spark’s full report on ELUT stock, click here.
More about Aziyo Biologics
Elutia Inc. is a pioneer in drug-eluting biomatrix technologies, focusing on developing and commercializing products that enhance compatibility between medical devices and patients. The company aims to humanize medicine, allowing patients to thrive without compromise, particularly in the growing field of implantable technologies.
Average Trading Volume: 175,180
Technical Sentiment Signal: Sell
Current Market Cap: $37.73M
For detailed information about ELUT stock, go to TipRanks’ Stock Analysis page.